These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30381544)

  • 1. Mitochondrial DNA content of peripheral blood mononuclear cells in ART untreated & stavudine/zidovudine treated HIV-1-infected patients.
    Subashini D; Dinesha TR; Srirama RB; Boobalan J; Poongulali S; Chitra DA; Mothi SN; Solomon SS; Saravanan S; Solomon S; Balakrishnan P
    Indian J Med Res; 2018 Aug; 148(2):207-214. PubMed ID: 30381544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
    Jones SP; Qazi N; Morelese J; Lebrecht D; Sutinen J; Yki-Jărvinen H; Back DJ; Pirmohamed M; Gazzard BG; Walker UA; Moyle GJ
    J Acquir Immune Defic Syndr; 2005 Dec; 40(5):565-72. PubMed ID: 16284533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
    van der Valk M; Casula M; Weverlingz GJ; van Kuijk K; van Eck-Smit B; Hulsebosch HJ; Nieuwkerk P; van Eeden A; Brinkman K; Lange J; de Ronde A; Reiss P
    Antivir Ther; 2004 Jun; 9(3):385-93. PubMed ID: 15259901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients.
    Maagaard A; Holberg-Petersen M; Kollberg G; Oldfors A; Sandvik L; Bruun JN
    Antivir Ther; 2006; 11(5):601-8. PubMed ID: 16964828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
    Nolan D; Hammond E; Martin A; Taylor L; Herrmann S; McKinnon E; Metcalf C; Latham B; Mallal S
    AIDS; 2003 Jun; 17(9):1329-38. PubMed ID: 12799554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.
    Casula M; Weverling GJ; Wit FW; Timmermans EC; Stek M; Lange JM; Reiss P
    J Infect Dis; 2005 Nov; 192(10):1794-800. PubMed ID: 16235179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients.
    Maagaard A; Holberg-Petersen M; Kvittingen EA; Sandvik L; Bruun JN
    HIV Med; 2006 Jan; 7(1):53-8. PubMed ID: 16313293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity.
    Sánchez-Conde M; de Mendoza C; Jiménez-Nacher I; Barreiro P; Gonzalez-Lahoz J; Soriano V
    HIV Clin Trials; 2005; 6(4):197-202. PubMed ID: 16214736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
    Reiss P; Casula M; de Ronde A; Weverling GJ; Goudsmit J; Lange JM
    HIV Med; 2004 Jan; 5(1):11-4. PubMed ID: 14731163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
    Saitoh A; Fenton T; Alvero C; Fletcher CV; Spector SA
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4236-42. PubMed ID: 17893156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
    J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood mitochondrial DNA/nuclear DNA (mtDNA/nDNA) ratio as a marker of mitochondrial toxicities of stavudine containing antiretroviral therapy in HIV-infected Malawian patients.
    Kampira E; Dzobo K; Kumwenda J; van Oosterhout JJ; Parker MI; Dandara C
    OMICS; 2014 Jul; 18(7):438-45. PubMed ID: 24816082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers.
    Poirier MC; Divi RL; Al-Harthi L; Olivero OA; Nguyen V; Walker B; Landay AL; Walker VE; Charurat M; Blattner WA;
    J Acquir Immune Defic Syndr; 2003 Jun; 33(2):175-83. PubMed ID: 12794551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
    McComsey GA; Paulsen DM; Lonergan JT; Hessenthaler SM; Hoppel CL; Williams VC; Fisher RL; Cherry CL; White-Owen C; Thompson KA; Ross ST; Hernandez JE; Ross LL
    AIDS; 2005 Jan; 19(1):15-23. PubMed ID: 15627029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.
    Miura T; Goto M; Hosoya N; Odawara T; Kitamura Y; Nakamura T; Iwamoto A
    J Med Virol; 2003 Aug; 70(4):497-505. PubMed ID: 12794710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
    Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
    J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.
    Hulgan T; Haubrich R; Riddler SA; Tebas P; Ritchie MD; McComsey GA; Haas DW; Canter JA
    AIDS; 2011 Jan; 25(1):37-47. PubMed ID: 20871389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
    Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
    J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis.
    Lewis W; Kohler JJ; Hosseini SH; Haase CP; Copeland WC; Bienstock RJ; Ludaway T; McNaught J; Russ R; Stuart T; Santoianni R
    AIDS; 2006 Mar; 20(5):675-84. PubMed ID: 16514297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine.
    Miró O; López S; Rodríguez de la Concepción M; Martínez E; Pedrol E; Garrabou G; Giralt M; Cardellach F; Gatell JM; Vilarroya F; Casademont J
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1550-5. PubMed ID: 15577406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.